AbbVie enters $90m agreement to develop multiple myeloma immunotherapy

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/undefined undefined)
(Image: Getty/undefined undefined)

Related tags: Immunotherapy, AbbVie, Multiple myeloma, Bispecific antibodies, Antibody, Biologics, Immune system

AbbVie and Teneobio enter an agreement to develop and commercialize an immunotherapeutic for the treatment of multiple myeloma using the latter’s proprietary anti-CD3 platform.

Through the agreement, the companies will use Teneobio’s anti-CD3 platform to develop TNB-383B, a B-cell maturation antigen (BCMA) targeting immunotherapy treatment.

TNB-383B is a bispecific antibody that targets both BCMA and CD3, using the body’s immune system to target and kill the surface protein BCMA on tumor cells. BCMA proteins support the survival of multiple myeloma cells.

Per the agreement, TeneoOne, an affiliate of Teneobio focused on developing biologics, will receive an upfront payment of $90m (€79.8m) to continue developing TNB-383B through Phase I clinical trials.

AbbVie will hold the right to acquire TeneoBio’s biologic development sect TeneoOne, for global development and commercialization of the therapy candidate.

Mohit Trikha, VP and head of oncology early development at AbbVie, said in a statement, "Multiple myeloma is one of the most common hematological cancers and an area of significant medical need. Teneobio's novel approach to T-cell redirection with TNB-383B has the potential to be a treatment option that may offer new hope for myeloma patients."

Teneobio is expected to begin the clinical program for TNB-383B in the first half of 2019.

Therapies used to target BCMA proteins for the treatment of multiple myeloma have been developed before, but many of these drug candidates​ were chimeric antigen receptor (CAR) T-cell therapies. Bluebird Bio and Celgene entered an agreement​ in March 2018 to co-develop a BCMA CAR-T cell therapy for the treatment of multiple myeloma.

Related news

Show more

Related products

show more

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...

Related suppliers

Follow us

Products

View more

Webinars